Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation
about
Genetics and biology of pancreatic ductal adenocarcinomaSynthetic lethality in lung cancer and translation to clinical therapiesSMARCE1 regulates metastatic potential of breast cancer cells through the HIF1A/PTK2 pathwayThe disparate origins of ovarian cancers: pathogenesis and prevention strategies.Systematic genomic and translational efficiency studies of uveal melanoma.Collateral Lethality: A new therapeutic strategy in oncologySmall cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.Chromatin Remodelers: From Function to Dysfunction.Brahma is required for cell cycle arrest and late muscle gene expression during skeletal myogenesisOutlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discoveryInflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseasesConcomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic typeBrg1 coordinates multiple processes during retinogenesis and is a tumor suppressor in retinoblastoma.The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.MYC interaction with the tumor suppressive SWI/SNF complex member INI1 regulates transcription and cellular transformation.SWI/SNF-Mediated Lineage Determination in Mesenchymal Stem Cells Confers Resistance to Osteoporosis.Variants in the SMARCA4 gene was associated with coronary heart disease susceptibility in Chinese han population.A rationale to target the SWI/SNF complex for cancer therapy.Vulnerabilities of mutant SWI/SNF complexes in cancer.Chromatin remodeler mutations in human cancers: epigenetic implications.Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex Inactivation.Exome sequencing of oral squamous cell carcinoma in users of Arabian snuff reveals novel candidates for driver genes.Defining a Cancer Dependency Map.The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.Epigenomic regulation of oncogenesis by chromatin remodeling.Marked for death: targeting epigenetic changes in cancer.SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1(neg)/CK7(pos)/HepPar-1(pos) immunophenotype.The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer.Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities.Chromatin-Remodeling Complex SWI/SNF Controls Multidrug Resistance by Transcriptionally Regulating the Drug Efflux Pump ABCB1.Induction of functional Brm protein from Brm knockout miceSWI/SNF proteins as targets in cancer therapy.Co-regulation of transcription by BRG1 and BRM, two mutually exclusive SWI/SNF ATPase subunits.A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.SMARCA2-regulated host cell factors are required for MxA restriction of influenza A viruses.PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
P2860
Q26765438-2672FB99-CD7D-4BAA-BB36-98A128A15289Q28072904-BB162D33-D481-4CA5-8196-338A70E0A26DQ28831292-364D8F9D-807D-4314-A0FA-CD382D4DC922Q30240709-D0F742AF-79F7-4F96-A9E3-11780FFA104EQ33778295-BD2E6F57-ED34-4F61-915A-807FDE472C7EQ34513800-F42BFD68-1962-49E6-86E3-17625942AA7AQ35096087-AF652B77-FFB8-432D-A056-425B1D56EA3BQ35609041-D3C56181-F991-4D0D-94DD-AD4A86D94452Q35808490-4AAE480C-FB86-46B5-85BC-F842D7E91CFCQ36004275-82133C11-A6B0-4007-B2C4-518F73F87598Q36050778-BC1BD2D2-293D-49DD-8C32-81953B2B1745Q36082984-F2951CFB-12D1-445A-BB62-37770DBDA162Q36299678-FC377343-CCB2-4091-B5F7-657DD2E1B6FAQ36420683-F0ACC57D-EC23-4A58-8F6E-2B430C458106Q36462514-CEB2788D-C9C8-407D-8130-14DE2E18F930Q36584337-0023D821-CB13-4A68-BC10-F4C411DD6BDCQ36584643-54B67EA1-C3F7-4FDB-BE65-E77D0BB259CCQ36800071-5C532F2B-1E82-4802-AE6B-BAD5284563CDQ37118720-050F9C2F-CD18-451F-85F0-8B05331A7A83Q37238318-39C8A239-24F7-4B5C-BECF-9E66B4AE1A4FQ37702520-7FABD030-CB9F-4D26-BF1C-EAD3A07943C9Q38220523-D1661F8E-7526-4AD4-B27F-1AF3BDF8C96DQ38247363-8110FBD1-5C24-462C-A9E7-19E4A6965498Q38261746-7CA5F6FC-C2C3-43F9-8CAB-E096B44D3D73Q38379487-A2976700-5408-4992-8CCA-3190624EAB9EQ38381880-B2D45A4D-B7BC-47E4-886D-23E92262388DQ38696195-907011BF-1CE7-4185-B0E9-368BD3C227F9Q38706007-DF2C6B8D-A199-4D06-BE6D-722DD2B9A3F9Q38709544-855DAB64-9DAD-4416-BCC4-20BE2A539425Q38747872-822E64F9-46CC-4F5F-91F4-17E9CEA02FD1Q38757918-805DE450-DF44-4F09-B563-B942825E8406Q38896059-939DC510-04ED-441C-A7F8-19B37CFEC6B0Q39229171-3B38F04A-2549-40D8-BCE4-9602737D9443Q41636714-F5247672-F562-4F02-AD4D-8F4B2B1B63E6Q41857096-58912A40-4E21-4E9E-B1F6-2F687E6DDD63Q42260609-F52E36A3-8CFB-46F0-A624-2C696677F5F5Q47133201-180F3CD7-A0C9-49A6-91CD-1E127C2047C2Q47172395-A94E0AD9-308D-4EF0-A6C9-4455883FA07AQ47546996-B407EDFB-29FC-42B8-9DD6-8B93D073C381Q47684416-23B0854C-7B0C-49E7-95BD-D645566CB46A
P2860
Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Residual complexes containing ...... ive of SMARCA4 (BRG1) mutation
@ast
Residual complexes containing ...... ive of SMARCA4 (BRG1) mutation
@en
Residual complexes containing ...... ive of SMARCA4 (BRG1) mutation
@en-gb
Residual complexes containing ...... ive of SMARCA4 (BRG1) mutation
@nl
type
label
Residual complexes containing ...... ive of SMARCA4 (BRG1) mutation
@ast
Residual complexes containing ...... ive of SMARCA4 (BRG1) mutation
@en
Residual complexes containing ...... ive of SMARCA4 (BRG1) mutation
@en-gb
Residual complexes containing ...... ive of SMARCA4 (BRG1) mutation
@nl
prefLabel
Residual complexes containing ...... ive of SMARCA4 (BRG1) mutation
@ast
Residual complexes containing ...... ive of SMARCA4 (BRG1) mutation
@en
Residual complexes containing ...... ive of SMARCA4 (BRG1) mutation
@en-gb
Residual complexes containing ...... ive of SMARCA4 (BRG1) mutation
@nl
P2093
P2860
P921
P3181
P356
P1476
Residual complexes containing ...... ive of SMARCA4 (BRG1) mutation
@en
P2093
Boris G Wilson
Katherine C Helming
William C Hahn
Xiaofeng Wang
Youngha Kim
Zainab Jagani
P2860
P304
P3181
P356
10.1128/MCB.01372-13
P407
P577
2014-01-13T00:00:00Z